Cargando...
Breaking Down the Evidence for Bevacizumab in Ovarian Cancer
Bevacizumab has been FDA-approved for use in combination with single-agent chemotherapy for platinum-resistant ovarian cancer; however, its optimal role remains unclear. In this editorial, the timing, efficacy, safety, and rationale for use of bevacizumab in ovarian cancer are discussed.
Gardado en:
| Publicado en: | Oncologist |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
AlphaMed Press
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4319628/ https://ncbi.nlm.nih.gov/pubmed/25601962 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0302 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|